Gujarat Terce Laboratories
41.00
+0.68(+1.69%)
Market Cap₹30.40 Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D+1.69%
1M-5.51%
6M-5.57%
1Y-40.73%
5Y+468.65%
View Company Insightsright
More news about Gujarat Terce Laboratories
26Jul 25
Gujarat Terce Laboratories Reports Net Loss Despite Revenue Growth, Settles Tax Disputes
Gujarat Terce Laboratories Limited reported a 3.93% increase in total revenue to ₹50.20 crore, with sales rising 4.58% to ₹50.20 crore. EBITDA surged 143.12% to ₹3.89 crore, improving the EBITDA margin from 3.31% to 7.75%. However, the company faced a net loss of ₹0.98 crore due to a one-time tax settlement provision of ₹3.42 crore. The company reduced its debt-to-equity ratio from 0.54 to 0.15 and achieved zero borrowing in Q4. Operational improvements included better inventory and receivables management.
 no imag found
1 Year Returns:-40.73%
Industry Peers
Sun Pharmaceutical
1,723.60
(-0.05%)
Divis Laboratories
6,296.50
(+0.09%)
Torrent Pharmaceuticals
4,263.60
(+0.52%)
Dr Reddys Laboratories
1,291.00
(+0.83%)
Cipla
1,326.40
(-1.10%)
Lupin
2,246.80
(+1.23%)
Zydus Life Science
903.55
(+0.31%)
Mankind Pharma
2,023.40
(-0.04%)
Aurobindo Pharma
1,164.90
(+0.53%)
Alkem Laboratories
5,410.00
(+0.33%)